Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Tani

Showing results (521-530 of 532) with videos related to

Pageof 54
Sort By:
Immunological Reviews|January 4, 2001
Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulationD Huang, Y Han, M R Rani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2008
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patientsP L Zinzani, M Tani, S Fanti, et al.
Clinics (Sao Paulo, Brazil)|May 29, 2015
Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 casesAline Lopes Chagas, Luciana Kikuchi, Paulo Herman, et al.
Journal of Neuroimmunology|July 17, 1999
Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitorsV A Folcik, T Smith, S O'Bryant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2011
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphomaP L Zinzani, M Tani, A Pulsoni, et al.
American Journal of Clinical Oncology|October 1, 2014
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging SystemLuciana Kikuchi, Claudia P Oliveira, Mario R Alvares-da-Silva, et al.
Seminars in Oncology|April 1, 1997
Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of JapanS Kawai, M Tani, J Okamura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patientsP L Zinzani, F Gherlinzoni, S Storti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2023
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trialM Ladetto, R Tavarozzi, M Zanni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2024
Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047]T M Kim, M Taszner, S Novelli, et al.
Pageof 54

Showing results (521-530 of 532) with videos related to

Sort By:
Pageof 54
Immunological Reviews|January 4, 2001
Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulationD Huang, Y Han, M R Rani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2008
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patientsP L Zinzani, M Tani, S Fanti, et al.
Clinics (Sao Paulo, Brazil)|May 29, 2015
Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 casesAline Lopes Chagas, Luciana Kikuchi, Paulo Herman, et al.
Journal of Neuroimmunology|July 17, 1999
Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitorsV A Folcik, T Smith, S O'Bryant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2011
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphomaP L Zinzani, M Tani, A Pulsoni, et al.
American Journal of Clinical Oncology|October 1, 2014
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging SystemLuciana Kikuchi, Claudia P Oliveira, Mario R Alvares-da-Silva, et al.
Seminars in Oncology|April 1, 1997
Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of JapanS Kawai, M Tani, J Okamura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patientsP L Zinzani, F Gherlinzoni, S Storti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2023
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trialM Ladetto, R Tavarozzi, M Zanni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2024
Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047]T M Kim, M Taszner, S Novelli, et al.
Pageof 54